Literature DB >> 32024404

A modified Camel and Cactus Test detects presymptomatic semantic impairment in genetic frontotemporal dementia within the GENFI cohort.

Katrina Moore1, Rhian Convery1, Martina Bocchetta1, Mollie Neason1, David M Cash1, Caroline Greaves1, Lucy L Russell1, Mica T M Clarke1, Georgia Peakman1, John van Swieten2, Lize Jiskoot2, Fermin Moreno3, Myriam Barandiaran3, Raquel Sanchez-Valle4, Barbara Borroni5, Robert Laforce6, Marie-Claire Doré6, Mario Masellis7, Maria Carmela Tartaglia8, Caroline Graff9, Daniela Galimberti10,11, James B Rowe12, Elizabeth Finger13, Matthis Synofzik14,15, Hans-Otto Karnath16, Rik Vandenberghe17, Alexandre de Mendonça18, Carolina Maruta19, Fabrizio Tagliavini20, Isabel Santana21, Simon Ducharme22, Chris Butler23, Alex Gerhard24, Johannes Levin25, Adrian Danek25, Markus Otto26, Jason D Warren1, Jonathan D Rohrer1.   

Abstract

Impaired semantic knowledge is a characteristic feature of some forms of frontotemporal dementia (FTD), particularly the sporadic disorder semantic dementia. Less is known about semantic cognition in the genetic forms of FTD caused by mutations in the genes MAPT, C9orf72, and GRN. We developed a modified version of the Camel and Cactus Test (mCCT) to investigate the presence of semantic difficulties in a large genetic FTD cohort from the Genetic FTD Initiative (GENFI) study. Six-hundred-forty-four participants were tested with the mCCT including 67 MAPT mutation carriers (15 symptomatic, and 52 in the presymptomatic period), 165 GRN mutation carriers (33 symptomatic, 132 presymptomatic), and 164 C9orf72 mutation carriers (56 symptomatic, 108 presymptomatic) and 248 mutation-negative members of FTD families who acted as a control group. The presymptomatic mutation carriers were further split into those early and late in the presymptomatic period (more than vs. within 10 years of expected symptom onset). Groups were compared using a linear regression model, adjusting for age and education, with bootstrapping. Performance on the mCCT had a weak negative correlation with age (rho = -0.20) and a weak positive correlation with education (rho = 0.13), with an overall abnormal score (below the 5th percentile of the control population) being below 27 out of a total of 32. All three of the symptomatic mutation groups scored significantly lower than controls: MAPT mean 22.3 (standard deviation 8.0), GRN 24.4 (7.2), C9orf72 23.6 (6.5) and controls 30.2 (1.6). However, in the presymptomatic groups, only the late MAPT and late C9orf72 mutation groups scored lower than controls (28.8 (2.2) and 28.9 (2.5) respectively). Performance on the mCCT correlated strongly with temporal lobe volume in the symptomatic MAPT mutation group (rho > 0.80). In the C9orf72 group, mCCT score correlated with both bilateral temporal lobe volume (rho > 0.31) and bilateral frontal lobe volume (rho > 0.29), whilst in the GRN group mCCT score correlated only with left frontal lobe volume (rho = 0.48). This study provides evidence for presymptomatic impaired semantic knowledge in genetic FTD. The different neuroanatomical associations of the mCCT score may represent distinct cognitive processes causing deficits in different groups: loss of core semantic knowledge associated with temporal lobe atrophy (particularly in the MAPT group), and impaired executive control of semantic information associated with frontal lobe atrophy. Further studies will be helpful to address the longitudinal change in mCCT performance and the exact time at which presymptomatic impairment occurs.

Entities:  

Keywords:  C9orf72; MAPT; frontotemporal dementia; genetics; progranulin; semantic knowledge

Mesh:

Substances:

Year:  2020        PMID: 32024404     DOI: 10.1080/23279095.2020.1716357

Source DB:  PubMed          Journal:  Appl Neuropsychol Adult        ISSN: 2327-9095            Impact factor:   2.248


  4 in total

1.  Temporal order of clinical and biomarker changes in familial frontotemporal dementia.

Authors:  Adam M Staffaroni; Melanie Quintana; Barbara Wendelberger; Hilary W Heuer; Lucy L Russell; Yann Cobigo; Amy Wolf; Sheng-Yang Matt Goh; Leonard Petrucelli; Tania F Gendron; Carolin Heller; Annie L Clark; Jack Carson Taylor; Amy Wise; Elise Ong; Leah Forsberg; Danielle Brushaber; Julio C Rojas; Lawren VandeVrede; Peter Ljubenkov; Joel Kramer; Kaitlin B Casaletto; Brian Appleby; Yvette Bordelon; Hugo Botha; Bradford C Dickerson; Kimiko Domoto-Reilly; Julie A Fields; Tatiana Foroud; Ralitza Gavrilova; Daniel Geschwind; Nupur Ghoshal; Jill Goldman; Jonathon Graff-Radford; Neill Graff-Radford; Murray Grossman; Matthew G H Hall; Ging-Yuek Hsiung; Edward D Huey; David Irwin; David T Jones; Kejal Kantarci; Daniel Kaufer; David Knopman; Walter Kremers; Argentina Lario Lago; Maria I Lapid; Irene Litvan; Diane Lucente; Ian R Mackenzie; Mario F Mendez; Carly Mester; Bruce L Miller; Chiadi U Onyike; Rosa Rademakers; Vijay K Ramanan; Eliana Marisa Ramos; Meghana Rao; Katya Rascovsky; Katherine P Rankin; Erik D Roberson; Rodolfo Savica; M Carmela Tartaglia; Sandra Weintraub; Bonnie Wong; David M Cash; Arabella Bouzigues; Imogen J Swift; Georgia Peakman; Martina Bocchetta; Emily G Todd; Rhian S Convery; James B Rowe; Barbara Borroni; Daniela Galimberti; Pietro Tiraboschi; Mario Masellis; Elizabeth Finger; John C van Swieten; Harro Seelaar; Lize C Jiskoot; Sandro Sorbi; Chris R Butler; Caroline Graff; Alexander Gerhard; Tobias Langheinrich; Robert Laforce; Raquel Sanchez-Valle; Alexandre de Mendonça; Fermin Moreno; Matthis Synofzik; Rik Vandenberghe; Simon Ducharme; Isabelle Le Ber; Johannes Levin; Adrian Danek; Markus Otto; Florence Pasquier; Isabel Santana; John Kornak; Bradley F Boeve; Howard J Rosen; Jonathan D Rohrer; Adam L Boxer
Journal:  Nat Med       Date:  2022-09-22       Impact factor: 87.241

2.  Uniform data set language measures for bvFTD and PPA diagnosis and monitoring.

Authors:  Adam M Staffaroni; Sandra Weintraub; Katya Rascovsky; Katherine P Rankin; Jack Taylor; Julie A Fields; Kaitlin B Casaletto; Argye E Hillis; Sladjana Lukic; Maria Luisa Gorno-Tempini; Hilary Heuer; Merilee A Teylan; Walter A Kukull; Bruce L Miller; Bradley F Boeve; Howard J Rosen; Adam L Boxer; Joel H Kramer
Journal:  Alzheimers Dement (Amst)       Date:  2021-02-20

Review 3.  Biomarkers for C9orf7-ALS in Symptomatic and Pre-symptomatic Patients: State-of-the-art in the New Era of Clinical Trials.

Authors:  Giorgia Querin; Maria Grazia Biferi; Pierre-Francois Pradat
Journal:  J Neuromuscul Dis       Date:  2022

4.  Cognitive composites for genetic frontotemporal dementia: GENFI-Cog.

Authors:  Jackie M Poos; Katrina M Moore; Jennifer Nicholas; Lucy L Russell; Georgia Peakman; Rhian S Convery; Lize C Jiskoot; Emma van der Ende; Esther van den Berg; Janne M Papma; Harro Seelaar; Yolande A L Pijnenburg; Fermin Moreno; Raquel Sanchez-Valle; Barbara Borroni; Robert Laforce; Mario Masellis; Carmela Tartaglia; Caroline Graff; Daniela Galimberti; James B Rowe; Elizabeth Finger; Matthis Synofzik; Rik Vandenberghe; Alexandre de Mendonça; Pietro Tiraboschi; Isabel Santana; Simon Ducharme; Chris Butler; Alexander Gerhard; Johannes Levin; Adrian Danek; Markus Otto; Isabel Le Ber; Florence Pasquier; John C van Swieten; Jonathan D Rohrer
Journal:  Alzheimers Res Ther       Date:  2022-01-19       Impact factor: 6.982

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.